Nebulized Fibrinolytic Agents Improve Pulmonary Fibrinolysis but Not Inflammation in Rat Models of Direct and Indirect Acute Lung Injury

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hofstra, Jorrit J ^a   Cornet, Alexander D ^a   Declerck, Paul J ^b   Dixon, Barry ^c   Aslami, Hamid ^a   Vlaar, Alexander P J ^a   Roelofs, Joris J ^a   van der Poll, Tom ^a   Levi, Marcel ^a   Schultz, Marcus J ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ST VINCENT S HOSPITAL   (Australia)

^d HERMES Critical Care Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRIN; FIBRINOLYTIC AGENT; LIPOPOLYSACCHARIDE; PLACEBO; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 MONOCLONAL ANTIBODY; SODIUM CHLORIDE; TENECTEPLASE; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; LUNG LAVAGE; LUNG PROTECTION; MALE; NEBULIZATION; NONHUMAN; PLASMINOGEN ACTIVATION; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROVOCATION TEST; PSEUDOMONAS AERUGINOSA; PULMONARY FIBRINOLYSIS; RAT; TREATMENT OUTCOME;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; INFLAMMATION; LUNG; MALE; NEBULIZERS AND VAPORIZERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84873602179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055262     Document Type: Article

References (34)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, et al. (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818-824.
2. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Wolthuis EK, et al. (2006) Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 28: 992-998.
3. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS, (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-a review. Critical care medicine 34: 871-877.
4. Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA, (2002) Coagulation and inflammation in acute lung injury. Thromb Haemost 88: 17-25.
5. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, et al. (2000) Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. American journal of respiratory and critical care medicine 161: 454-462.
6. Sawdey MS, Loskutoff DJ, (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. The Journal of clinical investigation 88: 1346-1353.
7. Seeger W, Stohr G, Wolf HR, Neuhof H, (1985) Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 58: 326-338.
8. Seeger W, Gunther A, Thede C, (1992) Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 262: L286-L291.
9. Ware LB (2006) Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 27: 337-349. 10.1055/s-2006-948288 [doi].
10. Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL, (2001) Wound-healing defects in mice lacking fibrinogen. Blood 97: 3691-3698.
11. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, et al. (1991) Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 261: L240-L248.
12. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, et al. (1989) Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84: 695-705.
13. (1997) A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 337: 1118-1123. 10.1056/NEJM199710163371603 [doi].
14. Choi G, Vlaar APJ, Schouten M, Van't Veer C, Van der Poll T, et al. (2007) Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 30: 423-428.
15. Choi G, Hofstra JJ, Roelofs JJ, Rijneveld AW, Bresser P, et al. (2008) Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 36: 204-210. 10.1097/01.CCM.0000292012.87482.F4 [doi].
16. Choi G, Hofstra JJ, Roelofs JJ, Florquin S, Bresser P, et al. (2007) Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Critical care medicine 35: 1362-1368.
17. Schoots IG, Levi M, van Vliet AnK, Declerck PJ, Maas AM, et al. (2004) Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. Thrombosis and haemostasis 91: 497-505.
18. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE, (1998) Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free radical biology & medicine 25: 184-188.
19. Debrock S, Declerck PJ, (1997) Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochimica et biophysica acta 1337: 257-266.
20. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, et al. (2002) Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. American journal of physiology Lung cellular and molecular physiology 282: L285-L290.
21. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, et al. (2010) Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 23: 105-111. 10.1089/jamp.2009.0779 [doi].
22. Choi G, Hofstra JJH, Roelofs JJTH, Rijneveld AW, Bresser P, et al. (2008) Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 36: 204-210.
23. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, et al. (1990) Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 18: 1413-1418.
24. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE, (1998) Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 25: 184-188.
25. Zhao Y, Sharma AK, Lapar DJ, Kron IL, Ailawadi G, et al. (2011) Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation. Am J Physiol Lung Cell Mol Physiol 300: L718-L729. ajplung.00227.2010 [pii];10.1152/ajplung.00227.2010 [doi].
26. Renckens R, Roelofs JJ, Stegenga ME, Florquin S, Levi M, et al. (2008) Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia. J Thromb Haemost 6: 660-668. JTH2892 [pii];10.1111/j.1538-7836.2008.02892.x [doi].
27. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, et al. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232-237. 10.1172/JCI118396 [doi].
28. Allen GB, Cloutier ME, Larrabee YC, Tetenev K, Smiley ST, et al. (2009) Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 296: L277-L285. 90475.2008 [pii];10.1152/ajplung.90475.2008 [doi].
29. Hua F, Ren W, Zhu L (2011) Plasminogen activator inhibitor type-1 deficiency exaggerates LPS-induced acute lung injury through enhancing Toll-like receptor 4 signaling pathway. Blood Coagul Fibrinolysis 22: 480-486. 10.1097/MBC.0b013e328346ef56 [doi].
30. Choi G, Schultz MJ, Levi M, van der Poll T, (2006) The relationship between inflammation and the coagulation system. Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 136: 139-144.
31. Kipnis E, Guery BtP, Tournoys A, Leroy X, Robriquet L, et al. (2004) Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock (Augusta, Ga) 21: 444-451.
32. Robriquet L, Collet F, Tournoys A, Prangere T, Neviere R, et al. (2006) Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respiratory research 7: 41.
33. Dixon B, Santamaria JD, Campbell DJ, (2008) A phase 1 trial of nebulised heparin in acute lung injury. Critical care (London, England) 12: R64.
34. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, et al. (2010) Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 14: R180. cc9286 [pii];10.1186/cc9286 [doi].